辽宁成大: 辽宁成大股份有限公司2024年年度股东会会议文件

Core Viewpoint - The company is facing a complex operating environment with a slight increase in revenue but a decline in net profit, emphasizing the need for strategic adjustments and risk management in its operations [8][10][11]. Group 1: Meeting and Voting Details - The shareholders' meeting is scheduled for June 13, 2025, with both on-site and online voting options available [2][5]. - The meeting will be presided over by Chairman Xu Biao, and shareholders registered by the cutoff date can attend and vote [2][3]. Group 2: Financial Performance - The company achieved a revenue of 11.289 billion yuan, a year-on-year increase of 4.70%, while the net profit attributable to shareholders was 210 million yuan, a decrease of 10.09% [8][10]. - The decline in net profit is attributed to decreased revenue from the biopharmaceutical segment and increased R&D expenses [9][10]. Group 3: Business Strategy and Development - The company is committed to a dual-driven development strategy focusing on the pharmaceutical and financial investment sectors, aiming to enhance operational stability and efficiency [8][16]. - Future plans include expanding vaccine product lines and exploring new business opportunities in biopharmaceuticals, with a focus on innovative vaccines and therapies [16][17]. Group 4: Governance and Compliance - The company has established a robust internal control system to ensure compliance with legal and regulatory requirements, enhancing corporate governance [13][28]. - The board of directors has held multiple meetings to ensure effective oversight and decision-making, maintaining transparency and accountability [13][28]. Group 5: Risk Management - The company is actively monitoring external economic conditions and industry trends to mitigate risks associated with market fluctuations and regulatory changes [21][24]. - Specific measures include optimizing customer structures and enhancing supply chain management to address potential credit risks and operational challenges [24][25].